{"id":51360,"date":"2026-08-05T01:30:00","date_gmt":"2026-08-04T23:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=128b8c98a7fbb416b3e3c5ff26cc5a69"},"modified":"2026-08-05T01:30:00","modified_gmt":"2026-08-04T23:30:00","slug":"diamedica-therapeutics-to-report-second-quarter-2026-financial-results-and-provide-a-business-update-august-11-2026-2","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=51360","title":{"rendered":"DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026"},"content":{"rendered":"

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its second quarter 2026 financial results will be released after the markets close on Monday, August 10th<\/sup>. DiaMedica will host a live conference call on Tuesday, August 11th<\/sup> at 8:00 AM Eastern Time \/ 7:00 AM Central Time to provide a business update and discuss financial results.<\/p><\/a><\/a>

\nConference Call details:<\/p>\n\n\n\n\n\n

\nDate:<\/p><\/td>

\nTuesday, August 11, 2026<\/p><\/td><\/tr>\n

\nTime:<\/p><\/td>

\n8:00 AM EDT \/ 7:00 AM CDT<\/p><\/td><\/tr>\n

\nWeb access:<\/p><\/td>

\nhttps:\/\/app.webinar.net\/d01wEPk9peA<\/a><\/p><\/td><\/tr>\n

\nDial In:<\/p><\/td>

\n(646) 357-8766<\/p><\/td><\/tr>\n

\nConference ID:<\/p><\/td>

\n2224408<\/p><\/td><\/tr>\n<\/table>

\nInterested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on the Company\u2019s website, under investor relations - events and presentations<\/a>, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until August 18, 2026, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 2224408#.<\/p>

\nAbout DiaMedica Therapeutics Inc.<\/i><\/b><\/p>

\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica\u2019s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company\u2019s website at www.diamedica.com<\/a>.<\/p> Contacts<\/b>

\nScott Kellen\nChief Financial Officer\nPhone: (763) 496-5118\nskellen@diamedica.com<\/a><\/p>

\nFor Investor Inquiries:\n<\/b>Mike Moyer\nManaging Director, LifeSci Advisors, LLC\nPhone: (617) 308-4306\nmmoyer@lifesciadvisors.com<\/a><\/p>

\nMedia Contact:\n<\/b>Madelin Hawtin\nLifeSci Communications\nmhawtin@lifescicomms.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-51360","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/51360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51360"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/51360\/revisions"}],"predecessor-version":[{"id":51361,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/51360\/revisions\/51361"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}